Fighting Modern Battles, Brawling a Breast Cancer From the Past: A New Combination Therapy Technique Combining a Platinum-based Agent and HDAC Inhibition Agent

Authors

Matthew I. Hyder, Ursinus CollegeFollow
Jackson D. Southern, Ursinus CollegeFollow

Document Type

Paper

Publication Date

4-23-2025

Faculty Mentor

Ramesh Dasari

Abstract

Carboplatin and tucidinostat are two often-used chemotherapeutic drugs in combating cancers. After seeding BT-549 cells in vitro and single-drug treatments were completed, IC50 values and treatment curves were determined for both drugs with CompuSyn software. The Tucidinostat IC50 value of 0.28614 µM indicates effective 50% inhibitory activity at less than one micromolar. Carboplatin treatment revealed an IC50 value of 273.792 µM, indicating ineffective treatment. Combination therapy revealed an antagonistic effect with a CI50 value of 210.406. This may be due to experimental errors with pipetting or cell seeding, or drug-ailment mismatch.

Comments

Presented as part of the Ursinus College Celebration of Student Achievement (CoSA) held April 23, 2025.

The downloadable file is a poster.

Recommended Citation

Hyder, Matthew I. and Southern, Jackson D., "Fighting Modern Battles, Brawling a Breast Cancer From the Past: A New Combination Therapy Technique Combining a Platinum-based Agent and HDAC Inhibition Agent" (2025). Biology Presentations. 48.
https://digitalcommons.ursinus.edu/biology_pres/48